Nimodipine (Nimotop)

Nimodipine is an approved drug for preventing certain neurological problems in people who have experienced a brain haemorrhage. It is being studied as a treatment for HIV-associated dementia.

The most frequent side-effect of nimodipine is decreased blood pressure. It may also cause heart irregularities, flushing, headache, gastrointestinal disorders, nausea and a feeling of warmth.

It comes either as yellow tablets or a liquid for intravenous infusion. It is manufactured by Bayer under the tradename Nimotop.

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.